A detailed history of Crossmark Global Holdings, Inc. transactions in Calliditas Therapeutics Ab stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 16,117 shares of CALT stock, worth $644,680. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,117
Holding current value
$644,680
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$38.0 - $41.55 $612,446 - $669,661
16,117 New
16,117 $655,000

Others Institutions Holding CALT

About Calliditas Therapeutics AB


  • Ticker CALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,624,800
  • Market Cap $1.06B
  • Description
  • Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...
More about CALT
Track This Portfolio

Track Crossmark Global Holdings, Inc. Portfolio

Follow Crossmark Global Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.